|
|
|
Dear Sir or Madam,
A new platform technology makes it possible to connect, label or release drug compounds on demand – like a snap fastener – while incidentally improving the pharmacological profile of a well-known antibiotic. Meanwhile, a new study shows how a precisely timed sequence of two antibiotic classes can not only kill dangerous pathogens more effectively, but also curb their resistance evolution. At the same time, a pharmaceutical giant is sending a clear signal with the acquisition of three vaccine companies for up to $3.8 billion: the future of infectious disease medicine lies in prevention.
Your bionity.com team
|
|
|
|
|
|
|
|
|
|
|
|
| Most-read news last week |  | | Europe is pooling billions to turn biotech companies into global champions ... |
|
| |  | | Not all ultra-processed foods are unhealthy ... |
|
| |  | | Enzymes as recycling heroes: Researches sustainable plastic recycling ... |
|
|
| | | Europe is pooling billions to turn biotech companies into global champions ... |
|
| | | Not all ultra-processed foods are unhealthy ... |
|
| | | Enzymes as recycling heroes: Researches sustainable plastic recycling ... |
|
|
|
|
| Most-read news last month | | | Coffee doesn’t just wake you up — it may help protect your body from aging ... |
|
| | | Miltenyi Biotec expands Cologne production site for clinical reagents ... |
|
| | | Cytospire Therapeutics announces oversubscribed £61 million Series A financing ... |
|
| | | Egg consumption is associated with a lower risk of Alzheimer’s Disease ... |
|
| | | One Molecule, Two Effects: A New Drug Concept to Treat Obesity and Type 2 Diabetes ... |
|
|
|
|
|
|
|
|
|
|
|
|
 | Always up to date with the bionity.com newsletter | |
|  | | Always up to date with the bionity.com newsletter |
| | |
|
|
|
|
|
Unsubscribe from newsletter
|
